204 related articles for article (PubMed ID: 23421998)
1. CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity.
Zhao R; Yang HY; Shin J; Phan L; Fang L; Che TF; Su CH; Yeung SC; Lee MH
Cell Cycle; 2013 Mar; 12(6):935-43. PubMed ID: 23421998
[TBL] [Abstract][Full Text] [Related]
2. Akt destabilizes p57 (Kip2) : Akt at the converging crossroad?
Lo HW
Cell Cycle; 2013 Mar; 12(6):870-1. PubMed ID: 23470457
[No Abstract] [Full Text] [Related]
3. CDK inhibitor p57 (Kip2) is negatively regulated by COP9 signalosome subunit 6.
Chen B; Zhao R; Su CH; Linan M; Tseng C; Phan L; Fang L; Yang HY; Yang H; Wang W; Xu X; Jiang N; Cai S; Jin F; Yeung SC; Lee MH
Cell Cycle; 2012 Dec; 11(24):4633-41. PubMed ID: 23187808
[TBL] [Abstract][Full Text] [Related]
4. P21-activated kinase 4 regulates the cyclin-dependent kinase inhibitor p57(kip2) in human breast cancer.
Li Y; Wang D; Zhang H; Wang C; Dai W; Cheng Z; Wang G; Li F
Anat Rec (Hoboken); 2013 Oct; 296(10):1561-7. PubMed ID: 23873832
[TBL] [Abstract][Full Text] [Related]
5. Expression of p21(Wafl/Cip1), p57(Kip2) and HER2/neu in patients with gallbladder cancer.
Puhalla H; Wrba F; Kandioler D; Lehnert M; Huynh A; Gruenberger T; Tamandl D; Filipits M
Anticancer Res; 2007; 27(3B):1679-84. PubMed ID: 17595796
[TBL] [Abstract][Full Text] [Related]
6. HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53.
Xue Y; Chen J; Choi HH; Phan L; Chou PC; Zhao R; Yang H; Santiago J; Liu M; Yeung GE; Yeung SC; Lee MH
Cell Cycle; 2012 Nov; 11(22):4181-90. PubMed ID: 23095642
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of the cyclin-dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis.
Guo H; Jing L; Cheng Y; Atsaves V; Lv Y; Wu T; Su R; Zhang Y; Zhang R; Liu W; Rassidakis GZ; Wei Y; Nan K; Claret FX
Hepatology; 2016 Mar; 63(3):898-913. PubMed ID: 26606000
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-21 inhibits p57Kip2 expression in prostate cancer.
Mishra S; Lin CL; Huang TH; Bouamar H; Sun LZ
Mol Cancer; 2014 Sep; 13():212. PubMed ID: 25216674
[TBL] [Abstract][Full Text] [Related]
9. EGCG-targeted p57/KIP2 reduces tumorigenicity of oral carcinoma cells: role of c-Jun N-terminal kinase.
Yamamoto T; Digumarthi H; Aranbayeva Z; Wataha J; Lewis J; Messer R; Qin H; Dickinson D; Osaki T; Schuster GS; Hsu S
Toxicol Appl Pharmacol; 2007 Nov; 224(3):318-25. PubMed ID: 17196232
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of p57kip² promotes cell invasion via LIMK/cofilin pathway in human nasopharyngeal carcinoma cells.
Chow SE; Wang JS; Lin MR; Lee CL
J Cell Biochem; 2011 Nov; 112(11):3459-68. PubMed ID: 21769918
[TBL] [Abstract][Full Text] [Related]
11. The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer.
Zohny SF; Baothman OA; El-Shinawi M; Al-Malki AL; Zamzami MA; Choudhry H
Cancer Biomark; 2017; 18(4):413-423. PubMed ID: 28106536
[TBL] [Abstract][Full Text] [Related]
12. The Cdk inhibitor p57(Kip2) controls LIM-kinase 1 activity and regulates actin cytoskeleton dynamics.
Vlachos P; Joseph B
Oncogene; 2009 Nov; 28(47):4175-88. PubMed ID: 19734939
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 promotes G(1)/S cell cycle progression through bidirectional regulation of cyclins and cyclin-dependent kinase inhibitors via the phosphatidylinositol 3-kinase/Akt pathway in developing rat cerebral cortex.
Mairet-Coello G; Tury A; DiCicco-Bloom E
J Neurosci; 2009 Jan; 29(3):775-88. PubMed ID: 19158303
[TBL] [Abstract][Full Text] [Related]
14. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Way TD; Kao MC; Lin JK
J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
[TBL] [Abstract][Full Text] [Related]
15. Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival.
Nakai S; Masaki T; Shiratori Y; Ohgi T; Morishita A; Kurokohchi K; Watanabe S; Kuriyama S
Int J Oncol; 2002 Apr; 20(4):769-75. PubMed ID: 11894123
[TBL] [Abstract][Full Text] [Related]
16. Ubiquitylation and proteasomal degradation of the p21(Cip1), p27(Kip1) and p57(Kip2) CDK inhibitors.
Lu Z; Hunter T
Cell Cycle; 2010 Jun; 9(12):2342-52. PubMed ID: 20519948
[TBL] [Abstract][Full Text] [Related]
17. Regulation of cardiomyocyte proliferation and myocardial growth during development by FOXO transcription factors.
Evans-Anderson HJ; Alfieri CM; Yutzey KE
Circ Res; 2008 Mar; 102(6):686-94. PubMed ID: 18218983
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA TALNEC2 plays an oncogenic role in breast cancer by binding to EZH2 to target p57
Qiao E; Chen D; Li Q; Feng W; Yu X; Zhang X; Xia L; Jin J; Yang H
J Cell Biochem; 2019 Mar; 120(3):3978-3988. PubMed ID: 30378143
[TBL] [Abstract][Full Text] [Related]
19. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
[TBL] [Abstract][Full Text] [Related]
20. TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57
Li X; Ruan X; Zhang P; Yu Y; Gao M; Yuan S; Zhao Z; Yang J; Zhao L
Oncogene; 2018 May; 37(21):2773-2792. PubMed ID: 29511350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
